Customers Demonstrate Value of PacBio Long-Read Solutions for Resolving Structural Variants, Targeted Sequencing and Isoform Sequencing Applications
MENLO PARK, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB ) today announced that data using its Single Molecule, Real-Time (SMRT ® ) Sequencing technology, including results from its Sequel™ System, will be featured in more than 35 presentations at the Advances in Genome Biology & Technology ( AGBT ) conference taking place February 13-16 in Hollywood Beach, Florida. PacBio is a silver sponsor for this year’s conference.
The data presented at the conference will underscore the value PacBio customers are seeing in applications such as resolving structural variants, targeted sequencing, isoform sequencing, and de novo assembly.
Kevin Corcoran, Senior Vice President of Market Development for Pacific Biosciences commented, “Each year we are excited to join our colleagues at the AGBT conference, and this year we are proud to reinforce our leadership in long-read sequencing with a number of presentations containing data from our newest platform, the Sequel System. Our customers are deriving great benefits from the system, and we are excited to feature two such users in our workshop who will share their recent successes. Also in the workshop our Chief Scientific Officer Jonas Korlach will discuss the Sequel roadmap, including our plans to continue performance and throughput increases in the coming years.”
The PacBio workshop will be on Wednesday, February 15 from 3:40-4:40 p.m. ET. Margaret Roy, M.S., Head of Genomics Sequencing at Calico Life Sciences, will talk about her experience using the Sequel System for de novo sequencing of the naked mole-rat genome, and Nezih Cereb, M.D., CEO & Co-founder of HistoGenetics, will discuss high-throughput HLA Class I whole gene and HLA Class II long-range typing using targeted sequencing on the PacBio ® RS II and Sequel platforms. The workshop will be hosted by Dr. Korlach, who will report on advances in SMRT Sequencing for high quality genomes, transcriptomes and epigenomes, as well as new chemistry and software updates .
A complete list of PacBio-related talks and company-sponsored special events at AGBT is available here .
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ: PACB ) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT ® ) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio ® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com .
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future availability, uses, quality or performance of, or benefits of using, products or technologies, product updates and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
Contacts Media: Nicole Litchfield 415.793.6468 nicole@bioscribe.com Investors: Trevin Rard 650.521.8450 ir@pacificbiosciences.com
